Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) has received an average broker rating score of 2.00 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Aevi Genomic Medicine’s rating score has declined by 14.3% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a 1 year consensus price target of $6.38 for the company and are predicting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned Aevi Genomic Medicine an industry rank of 200 out of 265 based on the ratings given to related companies.

Several analysts recently weighed in on the stock. Needham & Company LLC reduced their price objective on shares of Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, August 16th. Jefferies Group LLC reissued a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a research note on Thursday, September 28th.

Shares of Aevi Genomic Medicine (GNMX) remained flat at $$1.47 during trading on Thursday. The company’s stock had a trading volume of 104,577 shares, compared to its average volume of 334,968. Aevi Genomic Medicine has a 1-year low of $0.98 and a 1-year high of $6.89.

Aevi Genomic Medicine (NASDAQ:GNMX) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). During the same period in the prior year, the company earned ($0.29) EPS. equities analysts anticipate that Aevi Genomic Medicine will post -0.88 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/zacks-aevi-genomic-medicine-inc-gnmx-receives-average-recommendation-of-buy-from-brokerages/1714670.html.

In other news, CEO Michael F. Cola purchased 119,047 shares of the business’s stock in a transaction on Tuesday, October 17th. The shares were acquired at an average price of $1.26 per share, with a total value of $149,999.22. Following the completion of the transaction, the chief executive officer now owns 218,483 shares of the company’s stock, valued at approximately $275,288.58. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Garry Arthur Neil purchased 75,000 shares of the business’s stock in a transaction on Tuesday, October 17th. The shares were purchased at an average cost of $1.26 per share, for a total transaction of $94,500.00. Following the transaction, the insider now directly owns 114,774 shares of the company’s stock, valued at approximately $144,615.24. The disclosure for this purchase can be found here. Insiders have acquired 625,440 shares of company stock worth $787,433 in the last ninety days. Insiders own 15.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. TIAA CREF Investment Management LLC boosted its position in Aevi Genomic Medicine by 16.7% during the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 13,966 shares during the last quarter. Northern Capital Management LLC raised its holdings in shares of Aevi Genomic Medicine by 317.9% during the second quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 80,675 shares during the period. LMR Partners LLP acquired a new position in shares of Aevi Genomic Medicine during the second quarter valued at about $149,000. Birchview Capital LP raised its holdings in shares of Aevi Genomic Medicine by 88.2% during the second quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 60,000 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in shares of Aevi Genomic Medicine by 433.7% during the third quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 106,178 shares during the period. 12.95% of the stock is currently owned by institutional investors and hedge funds.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.